Charmaine Roson - Philippines

“The PFDA has issued an advisory reiterating the importance of proper interactions between healthcare professionals and manufacturer or distributor personnel to ensure patient welfare is the priority.”

Charmaine Roson
Principal Consultant
Asia Actual Philippines

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Philippines FDA Issues Advisory Reiteration Against Unethical Business Practices

Published on: January 13th, 2023

On December 29th, 2022 the Philippines FDA (PFDA) issued an advisory reiteration concerning unethical business practices, specifically in regards to companies that sell/manufacture Prescription Pharmaceutical Products and Medical Devices (PPPMD) and their relationship/interaction with healthcare professionals (HCPs). The advisory is based off the Administrative Order (A.O.) No. 2015-0053, “Implementing Guidelines on the Promotion and Marketing of Prescription Pharmaceutical Products and Medical Devices.” 

PFDA Guidelines for Ethical Behavior Between PPPMDs and HCPs

The main purpose of the guidelines outlined in A.O. 2015-0053 are to ensure fair and reasonable marketing practices are utilized when promoting medical devices and pharmaceutical products, ultimately keeping the emphasis on patient rights and welfare. The provisions of the Administrative Order that the PFDA are as follows:  

Interactions Between PPPMDs and Health Care Professionals 

  • The foundation of the relationship between the PPPMD industry and HCPs must be patient welfare at all times. Ethics and transparency are crucial in encouraging healthcare practices revolving around patient need/well-being.  
  • Accordingly, PPPMD companies must keep their contact with HCPs within accordance to (A.O.) No. 2015-0053, complying with all current laws and regulations.  

Promotional Information and Activities: 

  • No PPPMD companies may utilize an HCP to promote a specific medical device or pharmaceutical product in an advertisement. This includes all media, such as print, online/social media, or television/radio advertising.  
  • All marketing pertaining to medical devices or pharmaceutical products will be audited by the PFDA to ensure none of these provisions are disobeyed by a PPPMD. In the case that the PFDA finds an advertisement has violated the provisions, a number of penalties could be incurred, including a cease-and-desist order against the company or fines.  
  • Education related items including grants or scholarships cannot be offered to an HCP in exchange for the recommendation or prescription of pharmaceutical products. 

Recreation and Entertainment 

  • Entertainment and recreational activities cannot be provided on behalf of an HCP from a PPPMD company, including vacations, tickets to theater/music performances or sporting events.  
  • The aforementioned entertainment or recreational activities cannot be offered to an HCP regardless whether the PPPMD company has engaged the HCP for speaking/consulting purposes.  
  • During scientific meetings, entertainment/recreational/social activities will not be paid for by a PPPMD company.  
  • A PPPMD company is forbidden from paying the expenses incurred by family/guests of an HCP through travel or meals accumulated over the course of travel.  

Educational Items and Gifts 

  • Anything without direct effect on a patient or the work of an HCP is not permitted to be given by a PPPMD company to an HCP.  

Roles and Responsibilities 

  • A code of ethics for healthcare product promotion will be implemented by PPPMD companies to function in tandem with Administrative Order (A.O.) No. 2015-0053, engendering respect and ethical behavior between HCPs and PPPMD companies.  

These provisions laid forth by the FDA will be upheld by all stakeholders with the desired end result being the continued upholding of patient rights and welfare. Punishments for failing to follow these provisions include fines and more.  

Reporting Violations to the PFDA

In addition, the FDA has set up points of contact to report violations of this advisory, which are listed below:  

  • Telephone: 
  • CDRR – (02) 8809-5596 
  • CDRRHR – (02) 8857-1900 loc. 8301 

Understanding Medical Device Advertising Requirements

It is important to note that all medical device advertising in the Philippines has to be approved by either the Ad Standards Council or the PFDA, dependent on the content of the ad. The requirements for these advertisements can be found here. More information on the requirements for advertising medical devices and pharmaceutical products in the Philippines can be found on the Asia Actual website here 

Additionally, across Asia, several different countries have rules/regulations in regard to medical device advertising and how it must get approved. For more information on the requirements for getting medical device advertising approved in in Thailand, the Philippines, Indonesia, Vietnam, Malaysia, Singapore, Korea, China, Hong Kong, Taiwan, and Japan, check this article on the Asia Actual website here 

Grow With Us

Please contact us if you have questions regarding the new regulations and/or are interested in registering your product in the Philippines. Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in each market. Contact Asia Actual today with any questions or support requests. 

Asia Actual is a regulatory consulting company specializing in helping manufacturers grow their sales through independent license holding, direct fulfillment, and a variety of sales channel support services. 


Blog Posts

CDSCO Issues Updates to IVD Classification List in India

The Central Drugs Standard Control Organisation (CDSCO) of India issued a notice (PDF) on October 25, 2023 classifying in-vitro diagnostic (IVD) medical devices under medical device rules. The updates to IVD classification in India include intended use, associated risk, and other parameters.

Embracing Innovation and Collaboration: Highlights from the 15th CII Global MedTech Summit

On October 6, 2023, a team of enthusiastic members from the AAI (Artificial Intelligence and Innovation) group, including Ashoniya Puri, Sanjay Singh, and Rajat Budhori, had the honor of attending the prestigious 15th CII Global MedTech Summit. Hosted by the Confederation of Indian Industry (CII), one of India's largest industry bodies, this event brought together key players in the MedTech sector, both from India and abroad. The summit revolved around the central theme, "Paving the way for a USD 50 billion MedTech Industry by 2030," signifying a collective vision for the industry's future growth.


On September 18, 2023, The Directorate General of Drug Administration (DGDA) published the Drug and Cosmetics Act 2023 formalizing the regulatory requirements of medical and diagnostic devices in Bangladesh with immediate effect.  A translated version of the document is available on Asia Actual’s website here.  All medical devices now require a Marketing Authorization Certificate to clear Customs and be sold on the market in Bangladesh.